CN113209357A - Composite styptic powder - Google Patents
Composite styptic powder Download PDFInfo
- Publication number
- CN113209357A CN113209357A CN202110531300.2A CN202110531300A CN113209357A CN 113209357 A CN113209357 A CN 113209357A CN 202110531300 A CN202110531300 A CN 202110531300A CN 113209357 A CN113209357 A CN 113209357A
- Authority
- CN
- China
- Prior art keywords
- formula
- hemostatic powder
- amino
- powder
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 135
- 239000002131 composite material Substances 0.000 title claims abstract description 62
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 121
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- -1 amino, succinimide ester Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 12
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 12
- 125000003172 aldehyde group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 229960002317 succinimide Drugs 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229920001410 Microfiber Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229910021536 Zeolite Inorganic materials 0.000 claims description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 239000003658 microfiber Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 2
- 239000004627 regenerated cellulose Substances 0.000 claims description 2
- 239000010457 zeolite Substances 0.000 claims description 2
- 239000000565 sealant Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 17
- 238000006731 degradation reaction Methods 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000000740 bleeding effect Effects 0.000 abstract description 7
- 230000003993 interaction Effects 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 description 25
- 239000000463 material Substances 0.000 description 14
- 238000005303 weighing Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 229920002994 synthetic fiber Polymers 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000593 degrading effect Effects 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000013168 hemostasis test Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides composite hemostatic powder, which is formed by mixing synthetic molecules 1, synthetic molecules 2 and water-absorbing powder, wherein the synthetic molecules 1 and the synthetic molecules 2 can react with each other to form gel in the presence of blood, so that the strength and the interaction capacity with tissues of the hemostatic powder are enhanced. The composite hemostatic powder can absorb a large amount of water, and the degradation time can be adjusted to be suitable for different bleeding positions and bleeding degrees.
Description
Technical Field
The invention relates to a composite hemostatic powder system, in particular to a composite hemostatic powder system based on controllable crosslinking and degradation synthetic material powder and water absorption powder, and a preparation method and application thereof.
Background
Throughout the development of hemostatic materials, the following four stages are experienced: one is a non-degradable material represented by vaseline oil yarn, which is simple to manufacture and is packed by compression to stop bleeding. The hemostatic material has poor hemostatic effect, is non-degradable, is easy to adhere to the blood crust, and is easy to cause the blood crust to fall off in the process of taking out, thereby causing secondary bleeding. The other is non-degradable hydrogel material, represented by PVA, which has good blood sucking performance, but also has the problem of secondary bleeding caused by non-degradation during the taking out process. Third, degradable natural high molecular material, mainly polysaccharide such as starch, alginic acid, chitosan, etc., and protein such as collagen, etc. The material has good biocompatibility, can be absorbed by a human body in vivo, and does not need to be taken out for the second time, so that the problem of secondary bleeding of the wound caused in the process of taking out the material is avoided. However, the natural polymer has a large amount of hydrogen bonds, so that the hemostatic material has high rigidity, and the prepared sponge has high brittleness and poor elasticity, and the used patient has foreign body sensation and poor postoperative comfort. And the protein hemostatic materials such as collagen from animal bodies have potential risks of in vivo immune activation, microbial and viral infection and the like. The biodegradable polyurethane thermoplastic elastomer represented by poly epsilon-caprolactone/lactide-urethane is taken as a fourth-generation hemostatic material, and has the advantages of good elasticity, good hemostatic effect, degradability, outflow, no adhesion in a lumen, no need of cleaning and the like. Is a novel lumen hemostatic material which is competitively developed by scientists in various countries in recent years.
However, the existing hemostatic materials still have the disadvantages of slow degradation speed, insufficient strength, etc., so that it is necessary to develop new hemostatic materials to obtain the desired performance.
Disclosure of Invention
The invention aims to provide composite hemostatic powder based on controllable crosslinking and degrading synthetic material powder and hemostatic powder, and a preparation method and application thereof.
A composite hemostatic powder is formed by mixing two molecules of polyoxyethylene polyoxypropylene block copolymer, polyacrylic acid and polyethylene glycol derivatives, synthetic molecule 1 and synthetic molecule 2, wherein the synthetic molecule 1 and the synthetic molecule 2 can form chemical bond connection through chemical reaction in blood to form gel, the strength of the hemostatic powder is enhanced, and meanwhile, the hemostatic powder can interact with tissues, wherein the hemostatic powder can be water-absorbing substances such as natural polysaccharides, proteins and the like and derivatives thereof.
In the composite hemostatic powder, the synthetic molecule 1 can be any one of a formula I, a formula II and a formula III:
in each formula, m, n and p can be 28-123, and x represents the number of arms and can be 1-8.
Wherein R is1Is any one of amino, succinimide ester, aldehyde, mercapto, alkenyl, alkynyl, acrylate, methacrylate, and in some embodiments, R1Is amino, succinimidyl ester, mercapto, alkynyl or azido group;
in some embodiments, the synthetic molecule 1 may be any one of the following formulas 1) to 4):
1) as shown in formula I, wherein m is 10-35, n is 28-123, p is 10-50, x is 4, R1Is amino, aldehyde or succinimide ester;
2) as shown in formula II, wherein m is 38-112, in some embodiments m is 56, x is 2-4, R1Is amino, mercapto or aldehyde group;
3) as shown in formula III, wherein m is 36, x is 2, R1Is an amino group.
In some embodiments, the synthetic molecule 2 in the composite hemostatic powder may be any one of formula IV, formula V, and formula VI:
in the formula, m, n and p are 2-88, x represents the number of arms is 1-8, specifically 2, 4 and 6, wherein R2Is any one of amino, carboxyl, succinimidyl ester, aldehyde group, mercapto, alkenyl, alkynyl, acrylate group, preferably amino, succinimidyl ester, mercapto, alkynyl or azide group.
The synthetic molecule 1 and the synthetic molecule 2 are connected viaR1And R2Are chemically reacted.
The synthetic molecule 2 of the invention can be any one of the following 1) to 4):
1) as shown in formula IV, wherein m is 10-52, n is 12-20, p is 30-98, x is 4, R2Is a succinimide ester, amino or mercapto group
2) Shown as formula V, wherein m is 28-88, x is 4, R2Is amino, alkenyl or succinimide ester
3) The formula VI is shown in the specification, wherein m is 28-88, x is 1, and R is amino, succinimide ester or aldehyde group.
In some embodiments, the composite hemostatic powder is composed of a compound shown in formula III and a compound shown in formula V, wherein m is 36, x is 4, and R1 is amino or alkynyl; in the compound shown in the formula V, m is 28-46, x is 4, R2Is amino, alkenyl or succinimide ester.
In some embodiments, the composite hemostatic powder is composed of a compound shown as a formula II and a compound shown as a formula VI or a compound shown as a formula IV, wherein m in the compound shown as the formula II is 70-112, x is 2-4, and R is1Is amino, mercapto or aldehyde group; in the compound shown in the formula VI, m is 56, x is 4, and R2 is alkenyl; in the compound shown in the formula IV, m is 52, n is 12, p is 98, and x is 2.
In the composite hemostatic powder system based on the controllable cross-linking and degrading synthetic material powder and the hemostatic powder, the average particle size of the synthetic molecules 1 and 2 can be 0.01-10 mu m.
In the composite hemostatic powder, the hemostatic powder may be commercial hemostatic powder such as regenerated cellulose hemostatic powder, chitosan hemostatic powder, starch hemostatic powder, collagen hemostatic powder, zeolite hemostatic powder, and the like, and specifically may be: fuhe and Tai degradable hemostatic powder, Meisiter quick-acting hemostatic powder, Languan hemostatic powder, Alista hemostatic powder, Aiwei Titing microfiber hemostatic collagen, QuikClot and the like, and also can be water-absorbing powder, such as polysaccharide and derivatives thereof, and protein and derivatives thereof.
The polysaccharide or its derivative can be agar, agarose, sodium alginate, cellulose, starch, hyaluronic acid or their derivatives.
The proteins and their derivatives may be collagen, gelatin, thrombin, fibrin or their derivatives.
In some embodiments, the synthetic molecule 1, the synthetic molecule 2 and the water-absorbing powder are uniformly mixed according to a certain proportion, so that a composite hemostatic powder system based on the synthetic material powder and the water-absorbing powder with controllable crosslinking and degradation can be prepared.
In some embodiments, the mass ratio of the synthetic molecule 1, the synthetic molecule 2 and the water absorbent powder can be 0.01-10: 0.1-10: 0.01-10, in some embodiments 0.1-2: 0.1-2, in some embodiments 1: 1, and in other embodiments 1: 2: 1.
The composite hemostatic powder system based on the controllable cross-linking and degrading synthetic material powder and the water absorbing powder has controllable degradation time in a simulated body fluid environment and in vivo, and the degradation period is 1 hour to 10 days.
The composite hemostatic powder system based on the controllable cross-linking and degrading synthetic material powder and the water absorbing powder provided by the invention has potential application in the following fields:
(1) medical sponge;
(2) epidermal hemostasis;
(3) organ hemostasis;
(4) arterial hemostasis;
compared with the prior art, the invention has the following beneficial effects:
(1) compared with the commercially available hemostatic powder, the composite hemostatic powder has higher water absorption capacity, can quickly absorb blood at a wound bleeding part, concentrates blood coagulation factors and blood cells, and quickly activates endogenous blood coagulation;
(2) the composite hemostatic powder can closely interact with tissues, can be closely attached to the position of a wound to form a physical barrier layer, prevents blood from continuously flowing out, and does not need an additional method to fix the composite hemostatic powder;
(3) the degradation time of the composite hemostatic powder can be regulated and controlled, and the hemostatic requirements of wounds at different positions and different degrees are met;
(4) the composite hemostatic powder has good biocompatibility.
Description of the drawings:
FIG. 1 shows a block experimental diagram of femoral artery of pig according to the embodiment of the present invention.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Examples 1,
Weighing 140mg of four-arm polyethylene glycol amino group (shown as formula III, wherein m is 36, x is 4, R1Amino group) with a particle size of 1 μm, and weighing 110mg of four-arm polyacrylamide (as shown in formula V, wherein m is 46, x is 4, and R is2Succinimidyl ester) with the particle diameter of 2 mu m, and uniformly mixing the synthetic powder with 100mg of starch water-absorbing powder to obtain the composite hemostatic powder.
And (3) degradation test: and (3) putting the absorbed composite hemostatic powder into a PBS (phosphate buffer solution) solution with the mass being 10 times that of the absorbed composite hemostatic powder, then putting the composite hemostatic powder into a constant-temperature shaking table at 37 +/-1 ℃, and observing the change condition of a gel sample in a buffer solution at the speed of 100r/min until no precipitate is seen after centrifugation, wherein the time is recorded as the gel in-vitro degradation time.
After the composite hemostatic powder prepared in the embodiment absorbs water, the composite hemostatic powder is gelatinous and can be well attached to the surface of skin, and the in-vitro degradation time is 5 days.
Examples 2,
Weighing 200mg six-arm polyoxyethylene polyoxypropylene amino (shown as formula I, wherein m is 10, n is 123, p is 50, x is 6, and R is1Amino group) with a particle size of 0.2 μm, 200mg of two-arm polyoxyethylene polyoxypropylene succinimide ester (shown in formula IV, wherein m is 10, n is 20, p is 30, x is 2, R2 is succinimidyl ester) with a particle size of 0.5 μmAnd m, uniformly mixing the two synthetic powders with 200mg of chitosan water absorption powder to obtain the composite hemostatic powder.
Water absorption capacity test method: mixing a certain mass of hemostatic powder, then spreading the mixture in a culture dish, and adding ultrapure water immersed hemostatic powder into the culture dish. And taking out the gelatinized hemostatic powder every other hour, wiping off the residual water on the surface, weighing the gel, weighing for 5 times, and taking the average value as the weighing mass. The weighed gel is placed in a culture dish and water is added again to swell the gel. The final mass was recorded as the three consecutive weighed masses no longer changed. The water absorption capacity calculation method is as follows:
HE: water absorption expansion times;
wt: the final quality of the hemostatic powder after water absorption and expansion;
w0: initial quality of the styptic powder before water absorption.
The water absorption capacity of the composite hemostatic powder prepared in the example is 300 times of that of the chitosan water absorption powder, after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 3 days.
Examples 3,
Weighing 100mg of eight-arm polyacrylamide amino (shown as formula II, wherein m is 38, x is 8, and R is1Amino group) with a particle size of 1.5 μm, and 200mg of eight-arm polyacrylamide succinimidyl ester (shown in formula V, wherein m is 88, x is 8, and R is2Is succinimide activated ester) with the grain diameter of 1.5 mu m, and the two synthetic powders are uniformly mixed with 500mg arista TM hemostatic powder to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 200 times, which is higher than that of a single Arista TM hemostatic powder sold in the market (70 times), after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 4 days.
Examples 4,
Weighing 400mg six-arm polyoxyethylene polyoxypropylene aldehyde group (shown as formula I, wherein m is 35, n is 28, p is 10, and x is6，R2Aldehyde group) with a particle size of 1.9 μm, 400mg of six-arm polyoxyethylene polyoxypropylene amino (represented by formula IV, wherein m is 28, n is 16, p is 60, x is 6, R is2Amino group) with the particle size of 1.9 μm, and mixing the two synthetic molecules with 400mg of QuikClot hemostatic powder sold in the market to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 198 times, which is higher than that (45 times) of the single QuikClot hemostatic powder sold in the market, and after water absorption, the composite hemostatic powder is gelatinous, and the in vitro degradation time is 4 days.
Examples 5,
Weighing 150mg of four-arm polyacrylamide mercapto group (shown as formula II, wherein m is 112, x is 4, R1Mercapto group) with particle size of 1.9 μm, and 150mg of four-arm polyethylene glycol alkenyl (shown in formula VI, wherein m is 56, x is 4, and R is2Alkenyl) with the grain diameter of 2.2 mu m, and uniformly mixing the two synthetic molecular powders with 400mg of chitosan hemostatic powder sold in the market to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 140 times, which is higher than that (45 times) of the single chitosan hemostatic powder sold in the market, and after water absorption, the composite hemostatic powder is gelatinous, and the in vitro degradation time is 5 days.
Examples 6,
Weighing 100mg of four-arm polyethylene glycol succinimidyl ester (shown in formula III, wherein m is 36, x is 4, and R is1Alkynyl) with a particle size of 0.03 μm, and weighing 100mg of four-arm polyacrylamide (as shown in formula V, wherein m is 28, x is 4, and R is2Amino group) with the grain diameter of 0.02 mu m, and uniformly mixing the two synthetic powders with 500mg of starch hemostatic powder to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 290 times, which is higher than that of the commercially available starch hemostatic powder (50 times), and after water absorption, the composite hemostatic powder is gelatinized and is degraded in vitro for 4 days.
Example 7,
Weighing 300mg of four-arm polyacrylamide mercapto (shown as formula II, wherein m is 70, R1Is a mercapto group, and the compound is a hydroxyl group,x is 2), the particle size is 0.6 μm, 200mg of two-arm polyoxyethylene polyoxypropylene succinimidyl ester (shown as formula IV, wherein m is 52, n is 12, p is 98, and x is 2) is weighed and is 0.2 μm, and the two synthetic powders are uniformly mixed with 500mg of commercially available Arista TM hemostatic powder to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in this example is 456 times, which is far higher than that of a single Arista TM hemostatic powder sold in the market (70 times), and after water absorption, the composite hemostatic powder is gelatinous, and the in vitro degradation time is 4 days.
Example 8,
Weighing 200mg of four-arm polyoxyethylene polyoxypropylene aldehyde group (shown as formula I, wherein m is 25, n is 75, p is 30, x is 4, and R is1Aldehyde group) with a particle size of 0.2 μm, and 200mg of a two-arm polyethylene glycol amino group (as shown in formula VI, wherein m is 88, x is 2, and R is2Amino group) with the grain diameter of 0.5 mu m, and uniformly mixing the two synthetic powders with 200mg of chitosan water absorption powder to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the example is 200 times of that of the chitosan water absorption powder, after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 3 days.
And (3) carrying out a porcine femoral artery cut-off hemostasis test: the left and right femoral arteries of the pig are exposed, cut off by using surgical scissors (figure 1), then hemostatic powder is coated on the hemostatic powder, bleeding is observed every 30 seconds, the time required for observing the non-flowing of blood is the hemostatic time, and the hemostatic effect graph of each embodiment is shown in the table I.
Table one: comparison of hemostatic effects of the composite hemostatic powders prepared in examples
Claims (10)
1. The composite hemostatic powder is characterized by being formed by mixing two molecules of polyoxyethylene polyoxypropylene block copolymer, polyacrylic acid or polyethylene glycol derivative, synthetic molecule 1 and synthetic molecule 2, wherein the synthetic molecule 1 is any one of formula I, formula II and formula III:
in the formula I, the formula II or the formula III, m, n and p are 28-123, and x is 1-8;
wherein R is1Is any one of amino, succinimide ester, aldehyde group, sulfhydryl, alkenyl, alkynyl, acrylate group and methacrylate group; the synthetic molecule 2 is any one of formula IV, formula V or formula VI:
in the formula IV, V or VI, m, n and p are 2-88, x is 1-8, R2Is any one of amino, carboxyl, succinimide ester, aldehyde group, sulfhydryl, alkenyl, alkynyl and acrylate group.
2. The composite hemostatic powder according to claim 1, wherein R is1Or R2Is amino, succinimidyl ester, mercapto, alkynyl or azide group.
3. The composite hemostatic powder according to claim 1, wherein the synthetic molecule 1 is any one of the following formulas 1) to 4):
1) as shown in formula I, wherein m is 10-35, n is 28-123, p is 10-50, x is 4, R1Is amino, aldehyde or succinimide ester;
2) as shown in formula II, wherein m is 38-112, x is 2-4, R1Is amino, mercapto or aldehyde group;
3) as shown in formula III, wherein m is 36, x is 2, R1Is an amino group.
4. The composite hemostatic powder according to claim 1, wherein the synthetic molecule 2 is any one of the following 1) to 4):
1) as shown in formula IV, wherein m is 10-52, n is 12-20, p is 30-98, x is 4, R2Is a succinimide ester, amino or mercapto group
2) Shown as formula V, wherein m is 28-88, x is 4, R2Is amino, alkenyl or succinimide ester
3) As shown in formula VI, wherein m is 28-88, x is 1, R2Is amino, succinimide ester or aldehyde group.
5. The composite hemostatic powder according to claim 3 or 4, wherein the composite hemostatic powder is composed of a compound represented by formula III and a compound represented by formula V, wherein m is 36, x is 4, R is1Is amino or alkynyl; in the compound shown in the formula V, m is 28-46, x is 4, R2Is amino, alkenyl or succinimide ester.
6. The composite hemostatic powder according to claim 3 or 4, wherein the composite hemostatic powder is composed of a compound represented by formula II, wherein m is 70-112, x is 2-4, and R is a compound represented by formula VI or a compound represented by formula IV1Is amino, mercapto or aldehyde group; in the compound shown in the formula VI, m is 56, x is 4, and R2 is alkenyl; in the compound shown in the formula IV, m is 52, n is 12, p is 98, and x is 2.
7. The composite hemostatic powder according to claim 1, wherein the average particle size of the synthetic molecule 1 and the synthetic molecule 2 is 0.01 to 10 μm.
8. The composite hemostatic powder according to claim 1, further comprising a water absorbent powder, wherein the mass ratio of the synthetic molecule 1, the synthetic molecule 2 and the water absorbent powder is 0.01-10: 0.1-10: 0.0 l-10.
9. The composite hemostatic powder according to claim 8, wherein the water-absorbing powder is regenerated cellulose hemostatic powder, chitosan hemostatic powder, starch hemostatic powder, collagen hemostatic powder, or zeolite hemostatic powder, and specifically comprises: fuhe and Tai degradable hemostatic powder, Meisiter quick-acting hemostatic powder, Languan hemostatic powder, Alista hemostatic powder, Aiwei Titing microfiber hemostatic collagen and QuikClot, polysaccharide and derivatives thereof, and protein and derivatives thereof.
10. The use of the composite hemostatic powder of claim 8 as or in the preparation of medical sponges, epidermal hemostatic sealants and organ hemostatic sealants.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110531300.2A CN113209357B (en) | 2021-05-14 | 2021-05-14 | Composite styptic powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110531300.2A CN113209357B (en) | 2021-05-14 | 2021-05-14 | Composite styptic powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113209357A true CN113209357A (en) | 2021-08-06 |
| CN113209357B CN113209357B (en) | 2023-02-17 |
Family
ID=77092095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110531300.2A Active CN113209357B (en) | 2021-05-14 | 2021-05-14 | Composite styptic powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113209357B (en) |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284146A (en) * | 2001-07-17 | 2008-10-15 | 巴克斯特国际有限公司 | Dry hemostatic compositions and methods for their preparation |
| CN101338036A (en) * | 2007-07-06 | 2009-01-07 | 舒晓正 | Biocompatible quick-gelatinizing hydrogels and method for preparing spray thereof |
| US20090232877A1 (en) * | 2008-03-11 | 2009-09-17 | Materials Modification, Inc. | Method and composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding |
| WO2011124640A1 (en) * | 2010-04-07 | 2011-10-13 | Baxter International Inc. | Hemostatic sponge |
| US20130004478A1 (en) * | 2011-06-30 | 2013-01-03 | Yi-Lan Wang | Procoagulant Peptides and Their Derivatives and Uses Therefor |
| CN102911493A (en) * | 2012-09-28 | 2013-02-06 | 山东赛克赛斯药业科技有限公司 | Biodegradable medical hydrogel and preparation method and application thereof |
| US20130344131A1 (en) * | 2012-06-22 | 2013-12-26 | Z-Medica, Llc | Hemostatic devices |
| CN103957949A (en) * | 2011-10-11 | 2014-07-30 | 巴克斯特国际公司 | Hemostatic compositions |
| CN104399109A (en) * | 2014-11-26 | 2015-03-11 | 沈伟 | Gel hemostatic material composition and preparation method thereof |
| CN105169469A (en) * | 2015-08-29 | 2015-12-23 | 北京诺康达医药科技有限公司 | Tissue sealant and preparation method and application thereof |
| CN108014365A (en) * | 2017-12-14 | 2018-05-11 | 沈伟 | A kind of sealer hydrogel and its kit and preparation method |
| CN108525016A (en) * | 2017-03-01 | 2018-09-14 | 中国科学院化学研究所 | PEG hydrogel and the preparation method and application thereof based on chemical bond capable of being fast degraded |
| CN109646709A (en) * | 2019-01-29 | 2019-04-19 | 青岛中腾生物技术有限公司 | A kind of medical hemostatic closed material of degradable absorption |
| KR20190054476A (en) * | 2017-11-13 | 2019-05-22 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Medical Absorbent Structure for Hemostatis and Wound Healing Comprising Adhesive Hydrogel Layer |
| CN110025821A (en) * | 2018-01-12 | 2019-07-19 | 北京环球利康科技有限公司 | Use the method for biocompatible hemostatic agent and the compositions-treated active hemorrhage of tissue sealant |
| CN110240712A (en) * | 2019-05-09 | 2019-09-17 | 大连理工大学 | The high stretching of tissue adhesion a kind of, high viscosity, self-healing double-network hydrogel and its preparation method and application |
| CN110522948A (en) * | 2019-08-29 | 2019-12-03 | 南京工业大学 | injectable hydrogel and preparation method and application thereof |
| CN111265711A (en) * | 2020-03-09 | 2020-06-12 | 北京爱特康医疗科技有限公司 | Tissue sealant powder, preparation process thereof and tissue sealant |
| CN111440310A (en) * | 2020-05-26 | 2020-07-24 | 中国科学院长春应用化学研究所 | Polyethylene glycol derivative, preparation method thereof and polyethylene glycol hydrogel capable of rapidly generating crosslinking reaction |
| CN111909401A (en) * | 2020-08-14 | 2020-11-10 | 杭州仪文生物医药有限公司 | Bi-component cross-linked medical composite material, preparation method and application thereof |
-
2021
- 2021-05-14 CN CN202110531300.2A patent/CN113209357B/en active Active
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284146A (en) * | 2001-07-17 | 2008-10-15 | 巴克斯特国际有限公司 | Dry hemostatic compositions and methods for their preparation |
| CN101338036A (en) * | 2007-07-06 | 2009-01-07 | 舒晓正 | Biocompatible quick-gelatinizing hydrogels and method for preparing spray thereof |
| US20090232877A1 (en) * | 2008-03-11 | 2009-09-17 | Materials Modification, Inc. | Method and composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding |
| WO2011124640A1 (en) * | 2010-04-07 | 2011-10-13 | Baxter International Inc. | Hemostatic sponge |
| US20130004478A1 (en) * | 2011-06-30 | 2013-01-03 | Yi-Lan Wang | Procoagulant Peptides and Their Derivatives and Uses Therefor |
| CN103957949A (en) * | 2011-10-11 | 2014-07-30 | 巴克斯特国际公司 | Hemostatic compositions |
| US20130344131A1 (en) * | 2012-06-22 | 2013-12-26 | Z-Medica, Llc | Hemostatic devices |
| CN102911493A (en) * | 2012-09-28 | 2013-02-06 | 山东赛克赛斯药业科技有限公司 | Biodegradable medical hydrogel and preparation method and application thereof |
| CN104399109A (en) * | 2014-11-26 | 2015-03-11 | 沈伟 | Gel hemostatic material composition and preparation method thereof |
| CN105169469A (en) * | 2015-08-29 | 2015-12-23 | 北京诺康达医药科技有限公司 | Tissue sealant and preparation method and application thereof |
| CN108525016A (en) * | 2017-03-01 | 2018-09-14 | 中国科学院化学研究所 | PEG hydrogel and the preparation method and application thereof based on chemical bond capable of being fast degraded |
| KR20190054476A (en) * | 2017-11-13 | 2019-05-22 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Medical Absorbent Structure for Hemostatis and Wound Healing Comprising Adhesive Hydrogel Layer |
| CN108014365A (en) * | 2017-12-14 | 2018-05-11 | 沈伟 | A kind of sealer hydrogel and its kit and preparation method |
| CN110025821A (en) * | 2018-01-12 | 2019-07-19 | 北京环球利康科技有限公司 | Use the method for biocompatible hemostatic agent and the compositions-treated active hemorrhage of tissue sealant |
| CN109646709A (en) * | 2019-01-29 | 2019-04-19 | 青岛中腾生物技术有限公司 | A kind of medical hemostatic closed material of degradable absorption |
| CN110240712A (en) * | 2019-05-09 | 2019-09-17 | 大连理工大学 | The high stretching of tissue adhesion a kind of, high viscosity, self-healing double-network hydrogel and its preparation method and application |
| CN110522948A (en) * | 2019-08-29 | 2019-12-03 | 南京工业大学 | injectable hydrogel and preparation method and application thereof |
| CN111265711A (en) * | 2020-03-09 | 2020-06-12 | 北京爱特康医疗科技有限公司 | Tissue sealant powder, preparation process thereof and tissue sealant |
| CN111440310A (en) * | 2020-05-26 | 2020-07-24 | 中国科学院长春应用化学研究所 | Polyethylene glycol derivative, preparation method thereof and polyethylene glycol hydrogel capable of rapidly generating crosslinking reaction |
| CN111909401A (en) * | 2020-08-14 | 2020-11-10 | 杭州仪文生物医药有限公司 | Bi-component cross-linked medical composite material, preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| HENRY T. PENG ET AL: "Experimental Optimization of an In Situ Forming Hydrogel for Hemorrhage Control", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: APPLIED BIOMATERIALS》 * |
| YAZHONG BU ET AL: "Synthesis and properties of hemostatic and bacteria-responsive in situ hydrogels for emergency treatment in critical situations", 《ACS APPLIED MATERIALS & INTERFACES》 * |
| 吴德成: "POSS改性的PEG类生物胶水用于术后伤口的封闭和愈合", 《中国化学会2017全国高分子学术论文报告会摘要集-主题F：生物医用高分子》 * |
| 柴家科: "一种适用于战创伤致命性大出血止血材料的研发", 《中华损伤与修复杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113209357B (en) | 2023-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10195312B2 (en) | Modified starch material of biocompatible hemostasis | |
| EP2203053B1 (en) | Modified starch material of biocompatible hemostasis | |
| CN110025821A (en) | Use the method for biocompatible hemostatic agent and the compositions-treated active hemorrhage of tissue sealant | |
| ES2711416T3 (en) | Fast-acting dry sealant material and methods for its use and manufacture | |
| WO2009076873A1 (en) | A biocompatible denatured starch sponge material | |
| US20230348699A1 (en) | Hydrophobically modified chitosan compositions | |
| CN103957948A (en) | Hemostatic compositions | |
| MXPA06013721A (en) | Medical adhesive and methods of tissue adhesion. | |
| CN112898598A (en) | Tissue adhesion hydrogel and preparation method and application thereof | |
| CN113372585A (en) | Preparation method and application of hydrogel with high-adhesion composite function | |
| CN115400260B (en) | Repairing gel containing recombinant humanized collagen and preparation method thereof | |
| JP2021504097A (en) | Hemostatic composition and container containing it | |
| CN113289052B (en) | Controllable cross-linking and degradation material and application thereof | |
| Si et al. | Dynamic dual-crosslinking antibacterial hydrogel with enhanced bio-adhesion and self-healing activities for rapid hemostasis in vitro and in vivo | |
| CN112023109B (en) | Self-repairing hemostatic film capable of being adhered and preparation method thereof | |
| WO2009043839A1 (en) | Coalescing carboxymethylchitosan-based materials | |
| CN113209357B (en) | Composite styptic powder | |
| CN113289051B (en) | PEG powder capable of being rapidly crosslinked and degraded and application thereof | |
| CN112007202B (en) | Adhesive healing-promoting hemostatic sponge and preparation method thereof | |
| CN113599568A (en) | Synthetic material powder and application thereof in hemostasis system | |
| CN113350565B (en) | Medical adhesive material for vessel closure and preparation method thereof | |
| CN116983461A (en) | Hemostatic sponge system based on liposome modification | |
| KR20230057168A (en) | Haemostatic composition comprising keratin conjugated fibrinogen hydrogel | |
| CN117986625A (en) | Procoagulant high-adhesion hydrogel and preparation method and application thereof | |
| CN118340930A (en) | Preparation method of hemostatic protein sponge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |